Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Nicotinamide adenine dinucleotide (NAD+) is an essential biomolecule involved in many critical processes. Its role as both a driver of energy production and a signaling molecule underscores its importance in health and disease. NAD+ signaling impacts multiple processes that are dysregulated in cancer, including DNA repair, cell proliferation, differentiation, redoxregulation, and oxidative stress. Distribution of NAD+ is highly compartmentalized, with each subcellular NAD+ pool differentially regulated and preferentially involved in distinct NAD+-dependent signaling or metabolic events. Emerging evidence suggests that targeting NAD+ metabolism is likely to repress many specific mechanisms underlying tumor development and progression, including proliferation, survival, metabolic adaptations, invasive capabilities, heterotypic interactions with the tumor microenvironment, and stress response including notably DNA maintenance and repair. Here we provide a comprehensive overview of how compartmentalized NAD+ metabolism in mitochondria, nucleus, cytosol, and extracellular space impacts cancer formation and progression, along with a discussion of the therapeutic potential of NAD+-targeting drugs in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
A pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175 · cited 1×
“, 2013), and talazoparib (de Bono et al., 2017; Litton et al., 2018) have been approved by the Food and Drug Administration (FDA) for treatment of gynecologic cancers (Fig.”
BackgroundTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“Under oxidative or hypoxic stress, promoting NADPH production through TIGAR (TP53-induced glycolysis and apoptosis regulator)-mediated diversion of glycolysis into PPP increases cell survival (Bensaad et al., 2006; Ko et al., 2016; Wanka, Steinbach, & Rieger, 2012) (Fig.”
BackgroundMediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor
Yu, S.-W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., & Dawson, V. L. (2002) · Science · doi:10.1126/science.1072221 · Cited by 1,826 · cited 1×
“Upon DNA damage, PARP1 activation consumes up to 80% nuclear NAD+ for massive ADP-ribosylation, especially poly ADP-ribosylation (PARylation) (Yu et al., 2002).”
BackgroundThe multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683 · cited 1×
“Serine biosynthesis from glucose requires NAD+-dependent 3-phosphoglycerate dehydrogenase that can be genomically amplified in cancer (Murphy et al., 2018; Possemato et al., 2011).”
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6
Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., Gellon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M. M., et al. (2006) · Cell · doi:10.1016/j.cell.2005.11.044 · Cited by 1,637
Ying, W. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1672 · Cited by 1,494 · cited 1×
“Although the cytosolic NAD+ and mitochondrial NAD+ pools are connected by glycolysis and oxidative phosphorylation (Ying, 2008), the exact mechanism of mitochondrial NAD+ regeneration remains unclear.”
BackgroundDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 2×
“Daratumumab is the first FDA-approved CD38-targeting drug with single-agent efficacy for RRMM (Dimopoulos et al., 2016; Lokhorst et al., 2015; Lonial et al., 2016; Mateos et al., 2018; Palumbo et al., 2016; Usmani et al., 2016).”
BackgroundSirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase
Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., Kim, J., Woo, J., Kim, J. H., Choi, B. H., et al. (2011) · Science · doi:10.1126/science.1207861 · Cited by 1,429
Fueling Immunity: Insights into Metabolism and Lymphocyte Function
Pearce, E. L., Poffenberger, M. C., Chang, C.-H., & Jones, R. G. (2013) · Science · doi:10.1126/science.1242454 · Cited by 1,363
NAD + repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D’Amico, D., Ropelle, E. R., Lutolf, M. P., Aebersold, R., et al. (2016) · Science · doi:10.1126/science.aaf2693 · Cited by 1,255 · cited 1×
“It has been shown that NAD+ repletion by NR supplementation improves mitochondrial function and enhances stem cell function in aged mice (Zhang et al., 2016).”
BackgroundCantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238 · cited 1×
“Additionally, supplementation of NR increases mitochondrial NAD+ level both in cultured cells and the mouse liver (Cantó et al., 2012).”
BackgroundImmunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., & Wang, Y. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0023-5 · Cited by 1,223 · cited 1×
“MSCs also possess immunomodulatory properties, including suppression of T-cell proliferation, potentially contributing to immunosuppression (Krueger, Thorek, Meeker, Isaacs, & Brennen, 2019; Shi et al., 2018).”
BackgroundSwisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · cited 1×
“, 2010), rucaparib (Coleman et al., 2017; Swisher et al., 2017), niraparib (Mirza et al.”
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 2×
“Daratumumab is the first FDA-approved CD38-targeting drug with single-agent efficacy for RRMM (Dimopoulos et al., 2016; Lokhorst et al., 2015; Lonial et al., 2016; Mateos et al., 2018; Palumbo et al., 2016; Usmani et al., 2016).”
BackgroundResistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · cited 1×
“Notably, PARP inhibitors can induce reversion mutations in HRR genes that restore HRR function and promote drug resistance (Edwards et al., 2008; Lin et al., 2019).”
BackgroundRevollo, J. R., Grimm, A. A., & Imai, S.-I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408388200 · Cited by 1,010
Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., Lamming, D. W., Souza-Pinto, N. C., Bohr, V. A., Rosenzweig, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.035 · Cited by 950
Camacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., Nin, V., Escande, C., Warner, G. M., Puranik, A. S., Schoon, R. A., Reid, J. M., Galina, A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.006 · Cited by 901
Tao, R., Coleman, M. C., Pennington, J. D., Ozden, O., Park, S.-H., Jiang, H., Kim, H.-S., Flynn, C. R., Hill, S., Hayes McDonald, W., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.013 · Cited by 899 · cited 2×
“, 2016), and increasing cell resilience to environmental stress (Tao et al., 2010; Torrens-Mas, Pons, Sastre-Serra, Oliver, & Roca, 2017).”
BackgroundSIRT6 Promotes DNA Repair Under Stress by Activating PARP1
Mao, Z., Hine, C., Tian, X., Van Meter, M., Au, M., Vaidya, A., Seluanov, A., & Gorbunova, V. (2011) · Science · doi:10.1126/science.1202723 · Cited by 867 · cited 20×
“It has recently been shown that under normal conditions, PARP1 has limited NAD+ access that accounts for the basal unstimulated PARP1 activity; while upon DNA damage, PARP1 interaction with DNA strand breaks leads to full NAD+ access to its catalytic site and promotes allosteric activation of PARP1 (Langelier, Zandara…”
BackgroundInfluentialLonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 1×
“Daratumumab is the first FDA-approved CD38-targeting drug with single-agent efficacy for RRMM (Dimopoulos et al., 2016; Lokhorst et al., 2015; Lonial et al., 2016; Mateos et al., 2018; Palumbo et al., 2016; Usmani et al., 2016).”
BackgroundLysine glutarylation is a protein posttranslational modification regulated by SIRT5
Tan, M., Peng, C., Anderson, K. A., Chhoy, P., Xie, Z., Dai, L., Park, J., Chen, Y., Huang, H., Zhang, Y., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.014 · Cited by 844 · cited 1×
“SIRT5 is an inefficient deacetylase; instead it regulates its target protein activity by NAD+-dependent removal of malonyl, glutaryl, or succinyl groups from lysine residues (Du et al., 2011; Tan et al., 2014).”
BackgroundSelf-citationSIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle
Nakagawa, T., Lomb, D. J., Haigis, M. C., & Guarente, L. (2009) · Cell · doi:10.1016/j.cell.2009.02.026 · Cited by 787
Kim, H.-S., Patel, K., Muldoon-Jacobs, K., Bisht, K. S., Aykin-Burns, N., Pennington, J. D., van der Meer, R., Nguyen, P., Savage, J., Owens, K. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.023 · Cited by 785 · cited 1×
“, 2013), preserving mitochondrial membrane integrity (Kim et al., 2010; Yang et al., 2016), and increasing cell resilience to environmental stress (Tao et al.”
BackgroundSIRT3 Opposes Reprogramming of Cancer Cell Metabolism through HIF1α Destabilization
Finley, L. W. S., Carracedo, A., Lee, J., Souza, A., Egia, A., Zhang, J., Teruya-Feldstein, J., Moreira, P. I., Cardoso, S. M., Clish, C. B., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.014 · Cited by 782
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism
Sebastián, C., Zwaans, B. M. M., Silberman, D. M., Gymrek, M., Goren, A., Zhong, L., Ram, O., Truelove, J., Guimaraes, A. R., Toiber, D., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.047 · Cited by 660 · cited 1×
“SIRT6 regulates glucose homeostasis and suppresses the Warburg effect through inhibition of pyruvate kinase M2 (PKM2), the final rate-limiting step of glycolysis (Bhardwaj & Das, 2016; Sebastián et al., 2012) (Fig.”
BackgroundThe mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4
Csibi, A., Fendt, S.-M., Li, C., Poulogiannis, G., Choo, A. Y., Chapski, D. J., Jeong, S. M., Dempsey, J. M., Parkhitko, A., Morrison, T., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.023 · Cited by 586 · cited 1×
“, 2018), and that SIRT4 suppresses tumor growth by inhibiting glutamine metabolism (Csibi et al., 2013; Jeong et al., 2013; Wang et al., 2018).”
BackgroundBerger, F., Lau, C., Dahlmann, M., & Ziegler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508660200 · Cited by 508
Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation
Minhas, P. S., Liu, L., Moon, P. K., Joshi, A. U., Dove, C., Mhatre, S., Contrepois, K., Wang, Q., Lee, B. A., Coronado, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0255-3 · Cited by 501
Peiris-Pagès, M., Martinez-Outschoorn, U. E., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0712-6 · Cited by 465
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462 · cited 3×
“Notably, SIRT5mediated desuccinylation also inhibits peroxisomal acyl-CoA oxidase 1 (ACOX1) activity, reduces oxidative stress, and protects against the development of hepatocellular carcinoma (Chen et al., 2018).”
BackgroundJeong, S. M., Xiao, C., Finley, L. W. S., Lahusen, T., Souza, A. L., Pierce, K., Li, Y.-H., Wang, X., Laurent, G., German, N. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.024 · Cited by 445
Bell, E. L., Emerling, B. M., Ricoult, S. J. H., & Guarente, L. (2011) · Oncogene · doi:10.1038/onc.2011.37 · Cited by 440
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407
Biosensor reveals multiple sources for mitochondrial NAD +
Cambronne, X. A., Stewart, M. L., Kim, D., Jones-Brunette, A. M., Morgan, R. K., Farrens, D. L., Cohen, M. S., & Goodman, R. H. (2016) · Science · doi:10.1126/science.aad5168 · Cited by 407
NAD+ metabolism governs the proinflammatory senescence-associated secretome
Nacarelli, T., Lau, L., Fukumoto, T., Zundell, J., Fatkhutdinov, N., Wu, S., Aird, K. M., Iwasaki, O., Kossenkov, A. V., Schultz, D., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0287-4 · Cited by 402 · cited 3×
“p53-mediated inhibition of p38 MAPK, activating NF-κB signaling and promoting the protumorigenic inflammatory senescence-associated secretory phenotype (SASP) (Nacarelli et al., 2019).”
BackgroundInfluentialSirtuin functions and modulation: from chemistry to the clinic
Carafa, V., Rotili, D., Forgione, M., Cuomo, F., Serretiello, E., Hailu, G. S., Jarho, E., Lahtela-Kakkonen, M., Mai, A., & Altucci, L. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0224-3 · Cited by 387
Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth
Lin, R., Tao, R., Gao, X., Li, T., Zhou, X., Guan, K.-L., Xiong, Y., & Lei, Q.-Y. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.07.002 · Cited by 384
NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells
Ratajczak, J., Joffraud, M., Trammell, S. A. J., Ras, R., Canela, N., Boutant, M., Kulkarni, S. S., Rodrigues, M., Redpath, P., Migaud, M. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13103 · Cited by 378 · cited 1×
“Alternatively, extracellular NAD+ can be degraded to NMN, which is further metabolized by NR kinases (NRKs) to NR that can be imported as NAD+ precursors, likely through equilibrative nucleoside transporters (ENTs) (Nikiforov et al., 2011; Ratajczak et al., 2016).”
BackgroundPathways and Subcellular Compartmentation of NAD Biosynthesis in Human Cells
Nikiforov, A., Dölle, C., Niere, M., & Ziegler, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213298 · Cited by 326
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
Sampath, D., Zabka, T. S., Misner, D. L., O’Brien, T., & Dragovich, P. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.02.004 · Cited by 258
The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging
Chini, E. N., Chini, C. C. S., Espindola Netto, J. M., de Oliveira, G. C., & van Schooten, W. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.001 · Cited by 227
Cheng, Y., Ren, X., Gowda, A. S., Shan, Y., Zhang, L., Yuan, Y.-S., Patel, R., Wu, H., Huber-Keener, K., Yang, J. W., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.254 · Cited by 205 · cited 1×
“2), facilitating mtDNA repair (Cheng et al., 2013), preserving mitochondrial membrane integrity (Kim et al.”
BackgroundNAD synthase NMNAT acts as a chaperone to protect against neurodegeneration
Zhai, R. G., Zhang, F., Hiesinger, P. R., Cao, Y., Haueter, C. M., & Bellen, H. J. (2008) · Nature · doi:10.1038/nature06721 · Cited by 201 · cited 1×
“Of note, NMNAT not only functions as an enzyme, but also acts as a chaperone (Ruan, Zhu, Li, Brazill, & Zhai, 2015; Zhai et al., 2008), which could contribute to meeting the increased demand in maintaining proteostasis in rapidly adapting cancer cells (Calderwood & Murshid, 2017).”
BackgroundSelf-citationPARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
Dziadkowiec, K. N., Gąsiorowska, E., Nowak-Markwitz, E., & Jankowska, A. (2016) · Menopausal Review · doi:10.5114/pm.2016.65667 · Cited by 191
Inhibition of Nicotinamide Phosphoribosyltransferase
Pittelli, M., Formentini, L., Faraco, G., Lapucci, A., Rapizzi, E., Cialdai, F., Romano, G., Moneti, G., Moroni, F., & Chiarugi, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.136739 · Cited by 189
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
Galli, U., Colombo, G., Travelli, C., Tron, G. C., Genazzani, A. A., & Grolla, A. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00656 · Cited by 162
Grozio, A., Sociali, G., Sturla, L., Caffa, I., Soncini, D., Salis, A., Raffaelli, N., De Flora, A., Nencioni, A., & Bruzzone, S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.470435 · Cited by 158
Nicotinamide adenine dinucleotide is transported into mammalian mitochondria
Davila, A., Liu, L., Chellappa, K., Redpath, P., Nakamaru-Ogiso, E., Paolella, L. M., Zhang, Z., Migaud, M. E., Rabinowitz, J. D., & Baur, J. A. (2018) · eLife · doi:10.7554/elife.33246 · Cited by 142
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., & Ashworth, A. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201250 · Cited by 136
Piacente, F., Caffa, I., Ravera, S., Sociali, G., Passalacqua, M., Vellone, V. G., Becherini, P., Reverberi, D., Monacelli, F., Ballestrero, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3079 · Cited by 113
Blank, M. F., & Grummt, I. (2017) · Transcription · doi:10.1080/21541264.2016.1276658 · Cited by 111
Garavaglia, S., Bruzzone, S., Cassani, C., Canella, L., Allegrone, G., Sturla, L., Mannino, E., Millo, E., De Flora, A., & Rizzi, M. (2012) · Biochemical Journal · doi:10.1042/bj20111263 · Cited by 94 · cited 1×
“CD73 successively degrades NAD+ to NMN, and further to NR (Garavaglia et al., 2012; Grozio et al., 2013) (Fig.”
BackgroundMayer, P. R., Huang, N., Dewey, C. M., Dries, D. R., Zhang, H., & Yu, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178913 · Cited by 82
Identification of the nicotinamide salvage pathway as a new toxification route for antimetabolites
Buonvicino, D., Mazzola, F., Zamporlini, F., Resta, F., Ranieri, G., Camaioni, E., Muzzi, M., Zecchi, R., Pieraccini, G., Dölle, C., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.01.012 · Cited by 73 · cited 2×
“VAD rapidly depletes NAD+ pools, blocks glycolysis through inhibition of NAD +-dependent dehydrogenases, and significantly reduces the growth of NMNAT2-proficient neuroblastoma and melanoma xenografts (Buonvicino et al., 2018).”
BackgroundAntitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model
Sociali, G., Raffaghello, L., Magnone, M., Zamporlini, F., Emionite, L., Sturla, L., Bianchi, G., Vigliarolo, T., Nahimana, A., Nencioni, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6502 · Cited by 70
Du, Z., Liu, X., Chen, T., Gao, W., Wu, Z., Hu, Z., Wei, D., Gao, C., & Li, Q. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.037 · Cited by 56
Chan, M., Gravel, M., Bramoullé, A., Bridon, G., Avizonis, D., Shore, G. C., & Roulston, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0809 · Cited by 46
Cited by
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
NAD+ metabolism, stemness, the immune response, and cancer
Navas, L. E., & Carnero, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 517
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
Galli, U., Colombo, G., Travelli, C., Tron, G. C., Genazzani, A. A., & Grolla, A. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00656 · Cited by 162
Axonal energy metabolism, and the effects in aging and neurodegenerative diseases
Yang, S., Park, J. H., & Lu, H.-C. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00634-3 · Cited by 94
Self-citationDecoding the Rosetta stone of mitonuclear communication
English, J., Son, J. M., Cardamone, M. D., Lee, C., & Perissi, V. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105161 · Cited by 55
“terms of metabolic flux or NAD+-dependent signaling (Anderson et al., 2017; Davila et al., 2018; Zhu et al., 2019)”
Background
Metadata
- Authors
- Zhu, Y., Liu, J., Park, J., Rai, P., & Zhai, R. G.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 200
- Pages
- 27-41
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2936121830
- Cited by
- 79
- References
- 67
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.